Mounjaro Vs Zepbound: Complete Comparison
Mounjaro and Zepbound are essentially the same medication (tirzepatide) with different labels: Mounjaro is approved for type 2 diabetes and Zepbound is approved for weight loss, so your choice depends mainly on your diagnosis and insurance coverage.
If the Ozempic-versus-Wegovy comparison confused you, this one might feel familiar. Just as Novo Nordisk sells semaglutide under two brand names, Eli Lilly sells tirzepatide as both Mounjaro (for diabetes) and Zepbound (for weight management). Same molecule, different packaging, different FDA approvals, and sometimes very different insurance realities. Let us walk through what actually separates them.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide |
| FDA-Approved For | Type 2 diabetes | Chronic weight management |
| Approval Date | May 2022 | November 2023 |
| Manufacturer | Eli Lilly | Eli Lilly |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Average Weight Loss | ~15-22% (off-label data) | ~18-22% |
| List Price (monthly) | $1,000-$1,200/mo (brand) | $1,000-$1,200/mo (brand) |
How Mounjaro Works
Mounjaro delivers tirzepatide as a once-weekly subcutaneous injection. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two different incretin hormone receptors simultaneously .
When you eat, your gut releases GLP-1 and GIP to help regulate blood sugar and signal fullness. Tirzepatide amplifies both of these signals far beyond what your body produces naturally. The result is powerful appetite suppression, slower gastric emptying, improved insulin sensitivity, and enhanced fat metabolism.
Mounjaro was designed and studied primarily for blood sugar control in type 2 diabetes patients. The SURPASS clinical trial program demonstrated impressive A1C reductions, with many patients achieving levels below the diabetic threshold. Weight loss in those trials was substantial but was measured as a secondary outcome .
How Zepbound Works
Zepbound uses the exact same tirzepatide molecule at the exact same doses delivered through the exact same type of injection device. The pharmacology is identical because it is the same drug.
What differs is the FDA indication and the clinical data package behind it. Zepbound's approval was based on the SURMOUNT trial program, which studied tirzepatide specifically in people seeking weight loss. These trials enrolled patients based on BMI criteria (30+ or 27+ with comorbidities) rather than diabetes status, and the primary endpoint was percentage of body weight lost.
This matters from a regulatory and insurance perspective, even though the medication itself is the same. Having a weight management indication means that Zepbound can be prescribed on-label for weight loss, which can sometimes make insurance coverage more straightforward.
Efficacy Comparison: Weight Loss Results
Because Mounjaro and Zepbound contain the same active ingredient at the same doses, their weight loss potential is essentially identical when used at equivalent doses in similar patient populations.
The SURMOUNT-1 trial (used for Zepbound's approval) showed weight loss of 15% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg over 72 weeks in patients without diabetes . The SURPASS trials (used for Mounjaro's approval) showed similar magnitude of weight loss as a secondary outcome in patients with type 2 diabetes, though the exact percentages varied slightly because of the different patient population.
In practice, whether you take Mounjaro or Zepbound, you are getting tirzepatide. The weight loss you experience will depend on your dose, your adherence, your starting weight, your diet and activity level, and your individual metabolic response. The brand name on the box does not change the biochemistry.
One nuance worth noting: Mounjaro's diabetes trials enrolled patients with type 2 diabetes, who tend to lose slightly less weight on GLP-1 medications than non-diabetic patients. So the weight loss numbers from the SURPASS trials may appear slightly lower than the SURMOUNT numbers, but this reflects the patient population, not a difference in the drug. When non-diabetic patients use Mounjaro off-label for weight loss, they can expect results similar to what SURMOUNT showed for Zepbound.
Not every patient needs to reach the maximum 15 mg dose. Many achieve excellent results at 7.5 mg or 10 mg. Your physician will help find the dose that gives you the best balance of weight loss and tolerability, regardless of which brand name is on the prescription.
Side Effects Comparison
The side effects are identical because the medications are identical:
- Nausea: The most common side effect, affecting roughly 24-33% of patients in clinical trials .
- Diarrhea: Reported in approximately 15-23% of patients.
- Constipation: Affects about 10-17% of patients.
- Vomiting: Most common during dose escalation periods.
- Abdominal pain: Related to GI motility changes.
- Injection site reactions: Generally mild and temporary.
Serious but uncommon risks include pancreatitis, gallbladder disease, kidney injury, and the thyroid C-cell tumor warning from animal studies . Both carry the same boxed warning. Both are contraindicated in patients with medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Managing side effects is one of the most important aspects of tirzepatide treatment. At Form Blends, our physicians guide patients through each dose increase, adjust timing if needed, and provide dietary recommendations to minimize GI discomfort. Taking the injection after eating a small meal, staying well hydrated, and avoiding overly rich or fatty foods during the titration phase can make a significant difference in how patients feel during the adjustment period.
Cost Comparison
Here is where things actually diverge in a meaningful way. While the list prices are in the same ballpark (Mounjaro: approximately $1,000-$1,200/mo (brand) per month; Zepbound: approximately $1,000-$1,200/mo (brand) per month), insurance coverage often differs substantially.
If you have type 2 diabetes, your insurance is far more likely to cover Mounjaro because it has a diabetes indication. Many commercial plans include Mounjaro on their diabetes formulary. If you do not have diabetes and want tirzepatide for weight loss, Zepbound's weight management indication may be more relevant, but coverage for anti-obesity medications remains limited across many plans.
Eli Lilly has introduced various savings programs for both brands, including the LillyDirect platform and manufacturer coupons. These can significantly reduce out-of-pocket costs for eligible patients.
For patients who cannot access affordable brand-name tirzepatide through either channel, compounded tirzepatide through Form Blends offers a cost-effective alternative. Our physician-supervised programs use the same active ingredient at a fraction of the brand-name price.
One scenario we see frequently: a patient starts on Mounjaro through their endocrinologist, achieves great results, and then their insurance changes or the plan drops Mounjaro from its formulary. Rather than stopping treatment and risking weight regain, they transition to compounded tirzepatide through Form Blends. The medication is the same molecule at the same dose, just at a price that does not require insurance coverage.
Who Is Mounjaro Best For?
- Patients with type 2 diabetes who need both blood sugar management and weight loss
- Those whose insurance covers Mounjaro under their diabetes formulary
- Patients already established on Mounjaro with good results
- Anyone with a prescriber who is more familiar with Mounjaro than Zepbound
Who Is Zepbound Best For?
- Patients without type 2 diabetes whose primary goal is weight management
- Those whose insurance covers anti-obesity medications
- Patients who want an on-label weight loss prescription rather than off-label diabetes drug use
- Anyone who can access Zepbound through Eli Lilly's savings programs
Frequently Asked Questions
Are Mounjaro and Zepbound the same thing?
They contain the same active ingredient (tirzepatide) at the same doses, made by the same manufacturer. The difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Pharmacologically, they are identical.
Can I switch between Mounjaro and Zepbound?
Yes, switching is straightforward because they are the same medication. You can transition at the same dose without needing to re-titrate. The main reason patients switch is a change in insurance coverage or formulary status.
Do I need diabetes to get Mounjaro?
Mounjaro is FDA-approved for type 2 diabetes, but physicians can prescribe it off-label for weight management. Insurance coverage for off-label use may be limited, and many patients find it easier to use Zepbound (or compounded tirzepatide) for weight loss purposes.
Is one more effective than the other for weight loss?
No. Because they contain the same molecule at the same doses, their weight loss effectiveness is identical. Any differences in reported outcomes between the SURPASS and SURMOUNT trials reflect differences in the patient populations studied, not differences in the medication.
Can Form Blends help me access tirzepatide?
Absolutely. Form Blends offers physician-supervised compounded tirzepatide programs that provide the same active ingredient as Mounjaro and Zepbound at a significantly lower cost.
The Mounjaro versus Zepbound debate is ultimately a labeling and insurance question, not a medical one. The drug inside is identical. Your physician can help navigate which brand name makes the most sense for your insurance situation, or whether compounded tirzepatide is the most practical path. What matters is that you get access to this remarkable molecule at a price you can sustain for the long term.
Want to start tirzepatide without the brand-name price tag? Begin your free consultation with Form Blends today. Our medical team will evaluate your health profile, discuss your weight loss goals, and create a personalized treatment plan that works with your budget.